MedTrace Logo

Central China Rosai-Dorfman Disease Registry

NCT05284942 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-03-17

No results posted yet for this study

Summary

This is a research study among patients with Rosai-Dorfman disease.

Conditions

  • Rosai-Dorfman Disease
  • Langerhans Cell Histiocytosis

Interventions

DRUG

Mycophenolate mofetil combined with oral prednisone

Mycophenolate mofetil oral 500mg twice a day combined with standard of care of oral prednisone 5mg-15mg/day from baseline to week 108

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • AIHUA DU, M.d · Tongji Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-01
Primary Completion
2022-06-01
Completion
2022-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05284942 on ClinicalTrials.gov